Salarius Pharmaceuticals Inc. announced a significant update to its merger agreement with Decoy Therapeutics Inc. On June 10, 2025, the company entered into a Second Amendment to the Merger Agreement, prompted by substantial changes in market conditions. Since the execution of the original agreement in January 2025, the company's stock price has significantly decreased, affecting the exchange ratio. As a result, Salarius Pharmaceuticals' valuation was adjusted from $4.6 million to $2.31 million, leading to an increase of approximately 17 million shares of common stock to be issued to Decoy stockholders. Following this amendment, legacy stockholders of Salarius will retain 7.6% ownership, while Decoy's legacy stockholders will hold 92.4% of the combined company upon completion of the merger. This change reflects the shifting market landscape and aims to facilitate the completion of the transaction.